Document is current
Any future updates will be listed below
-
Authors
Sugitatsu, Yuya
Tomida, Akimasa
Suematsu, Masaya
Inoue, Tomoya
Kubo, Hiroshi
Nakazawa, Yozo
Yagyu, Shigeki https://orcid.org/0000-0003-4256-9783
Iehara, Tomoko
-
Funding
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (20K07641)
MEXT | Japan Society for the Promotion of Science (22K16328)
- License Information
-
More Information
Article History
Received: 1 January 2025
Revised: 16 January 2026
Accepted: 19 February 2026
First Online: 23 March 2026
Competing interests
: Shigeki Yagyu is the chief executive officer of A-SEEDS Co., Ltd. with equity, and Yozo Nakazawa is the executive officer of A-SEEDS Co., Ltd. with equity. Yozo Nakazawa and Shigeki Yagyu have applied for patents in the field of adoptive cell therapy in cancer.
: This study was approved by the Institutional Review Board of Kyoto Prefectural University of Medicine (approval number: 2019-111) and the Institutional Review Board of Shinshu University (approval no. 20-046_3). All in vivo experiments and procedures were conducted with the approval of the Institutional Review Board of Kyoto Prefectural University of Medicine (permit number: M2024-32). All experiments complied with the guidelines of the Declaration of Helsinki.
: All authors approved the manuscript and gave their consent for submission and publication.
